BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37823593)

  • 21. The promyelocytic leukemia protein isoform PML1 is an oncoprotein and a direct target of the antioxidant sulforaphane (SFN).
    Alhazmi N; Pai CP; Albaqami A; Wang H; Zhao X; Chen M; Hu P; Guo S; Starost K; Hajihassani O; Miyagi M; Kao HY
    Biochim Biophys Acta Mol Cell Res; 2020 Aug; 1867(8):118707. PubMed ID: 32243901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient mutations alter ATRX targeting to PML nuclear bodies.
    Bérubé NG; Healy J; Medina CF; Wu S; Hodgson T; Jagla M; Picketts DJ
    Eur J Hum Genet; 2008 Feb; 16(2):192-201. PubMed ID: 17957225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LYSP100-associated nuclear domains (LANDs): description of a new class of subnuclear structures and their relationship to PML nuclear bodies.
    Dent AL; Yewdell J; Puvion-Dutilleul F; Koken MH; de The H; Staudt LM
    Blood; 1996 Aug; 88(4):1423-6. PubMed ID: 8695863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HSV-1 genome subnuclear positioning and associations with host-cell PML-NBs and centromeres regulate LAT locus transcription during latency in neurons.
    Catez F; Picard C; Held K; Gross S; Rousseau A; Theil D; Sawtell N; Labetoulle M; Lomonte P
    PLoS Pathog; 2012; 8(8):e1002852. PubMed ID: 22912575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Swine Promyelocytic Leukemia Isoform II Inhibits Pseudorabies Virus Infection by Suppressing Viral Gene Transcription in Promyelocytic Leukemia Nuclear Bodies.
    Yu C; Xu A; Lang Y; Qin C; Wang M; Yuan X; Sun S; Feng W; Gao C; Chen J; Zhang R; Tang J
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32641476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PML bodies: a meeting place for genomic loci?
    Ching RW; Dellaire G; Eskiw CH; Bazett-Jones DP
    J Cell Sci; 2005 Mar; 118(Pt 5):847-54. PubMed ID: 15731002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling.
    Doucas V; Tini M; Egan DA; Evans RM
    Proc Natl Acad Sci U S A; 1999 Mar; 96(6):2627-32. PubMed ID: 10077561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PML nuclear bodies contribute to the basal expression of the mTOR inhibitor DDIT4.
    Salsman J; Stathakis A; Parker E; Chung D; Anthes LE; Koskowich KL; Lahsaee S; Gaston D; Kukurba KR; Smith KS; Chute IC; Léger D; Frost LD; Montgomery SB; Lewis SM; Eskiw C; Dellaire G
    Sci Rep; 2017 Mar; 7():45038. PubMed ID: 28332630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of the Zac1's transactivation and coactivation functions via PML and Daxx within distinct subcellular localizations.
    Ho CL; Huang YC; Tai CK; Liu ST; Wang JK; Wang WM; Huang SM
    Int J Biochem Cell Biol; 2010 Jun; 42(6):902-10. PubMed ID: 20097304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting PML in triple negative breast cancer elicits growth suppression and senescence.
    Arreal L; Piva M; Fernández S; Revandkar A; Schaub-Clerigué A; Villanueva J; Zabala-Letona A; Pujana M; Astobiza I; Cortazar AR; Hermanova I; Bozal-Basterra L; Arruabarrena-Aristorena A; Crespo JR; Valcarcel-Jimenez L; Zúñiga-García P; Canals F; Torrano V; Barrio R; Sutherland JD; Alimonti A; Martin-Martin N; Carracedo A
    Cell Death Differ; 2020 Apr; 27(4):1186-1199. PubMed ID: 31570853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Viral disruption of promyelocytic leukemia (PML) nuclear bodies by hijacking host PML regulators.
    Frappier L
    Virulence; 2011; 2(1):58-62. PubMed ID: 21217204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase 7 promotes PML sumoylation and is essential for PML nuclear body formation.
    Gao C; Ho CC; Reineke E; Lam M; Cheng X; Stanya KJ; Liu Y; Chakraborty S; Shih HM; Kao HY
    Mol Cell Biol; 2008 Sep; 28(18):5658-67. PubMed ID: 18625722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. THAP1 is a nuclear proapoptotic factor that links prostate-apoptosis-response-4 (Par-4) to PML nuclear bodies.
    Roussigne M; Cayrol C; Clouaire T; Amalric F; Girard JP
    Oncogene; 2003 Apr; 22(16):2432-42. PubMed ID: 12717420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PML represses lung cancer metastasis by suppressing the nuclear EGFR-mediated transcriptional activation of MMP2.
    Kuo HY; Huang YS; Tseng CH; Chen YC; Chang YW; Shih HM; Wu CW
    Cell Cycle; 2014; 13(19):3132-42. PubMed ID: 25486572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual roles for lysine 490 of promyelocytic leukemia protein in the transactivation of glucocorticoid receptor-interacting protein 1.
    Liu ST; Lu GY; Hsu YJ; Chang LC; Ho CL; Huang SM
    Biochim Biophys Acta; 2013 Aug; 1833(8):1799-810. PubMed ID: 23542129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic Profiling by ALaP-Seq Reveals Transcriptional Regulation by PML Bodies through DNMT3A Exclusion.
    Kurihara M; Kato K; Sanbo C; Shigenobu S; Ohkawa Y; Fuchigami T; Miyanari Y
    Mol Cell; 2020 May; 78(3):493-505.e8. PubMed ID: 32353257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation.
    Li Q; He Y; Wei L; Wu X; Wu D; Lin S; Wang Z; Ye Z; Lin SC
    Oncogene; 2011 Mar; 30(10):1194-204. PubMed ID: 21057547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PML positively regulates interferon gamma signaling.
    El Bougrini J; Dianoux L; Chelbi-Alix MK
    Biochimie; 2011 Mar; 93(3):389-98. PubMed ID: 21115099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of arsenic on the topology and solubility of promyelocytic leukemia (PML)-nuclear bodies.
    Hirano S; Udagawa O
    PLoS One; 2022; 17(5):e0268835. PubMed ID: 35594310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Promyelocytic leukemia protein (PML) controls breast cancer cell proliferation by modulating Forkhead transcription factors.
    Sachini N; Arampatzi P; Klonizakis A; Nikolaou C; Makatounakis T; Lam EW; Kretsovali A; Papamatheakis J
    Mol Oncol; 2019 Jun; 13(6):1369-1387. PubMed ID: 30927552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.